BPTHUS
After Hours
Back To Top
Last Updated: Dec 13, 2019 5:11 p.m. EST Delayed quote

$7.88

0.22 2.87%
After Hours Volume: 7
Health Care/Life Sciences 0.19%
Close Chg Chg %
$7.66 -0.05 -0.65% -0.05 -0.65%
Advanced Charting
  • $
  • %
  • Vol
Advanced Charting
55.44% vs Avg.
Volume: 68.5K 65 Day Avg. - 123.5K
Open: 7.67
Close: 7.66
7.37 Day Low/High 7.68
Day Range
1.61 52 Week Low/High 73.52

Your Watchlist

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

Symbol
Company
Price
Chg/Chg %
No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Uh oh

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Key Data

  • Open $7.67
  • Day Range 7.37 - 7.68
  • 52 Week Range 1.61 - 73.52
  • Market Cap $22.09M
  • Shares Outstanding 2.83M
  • Public Float 2.69M
  • Beta 0.53
  • Rev. per Employee n/a
  • P/E Ratio n/a
  • EPS $-5.35
  • Yield n/a
  • Dividend n/a
  • Ex-Dividend Date n/a
  • Short Interest 144.83K 11/29/19
  • % of Float Shorted 5.39%
  • Average Volume 123.48K

Performance

5 Day
  • -3.65%
1 Month
  • -28.18%
3 Month
  • -35.52%
YTD
  • 118.86%
1 Year
  • 47.31%

Recent News

  • MarketWatch
  • WSJ

Bio-Path's stock rockets after withdrawal of stock offering

UPDATE: Bio-Path stock gains another 130% on Thursday

No Headlines Available

Recent News

  • Other News
  • Press Releases

Bio-Path (BPTH) Upgraded to Buy: Here's What You Should Know

Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

on Zacks.com

NTNX, DKS among premarket gainers

NTNX, DKS among premarket gainers

on Seeking Alpha

ACB, AMTD, BZUN, CGC and INMD among midday movers

ACB, AMTD, BZUN, CGC and INMD among midday movers

on Seeking Alpha

AMTD, SCHW, CGC among premarket gainers

AMTD, SCHW, CGC among premarket gainers

on Seeking Alpha

Bio-Path Earnings: BPTH Stock Moves on Q3 Results

Bio-Path Earnings: BPTH Stock Moves on Q3 Results

on InvestorPlace.com

Bio-Path Holdings, Inc (BPTH) CEO Peter Nielsen on Q3 2019 Results - Earnings Call Transcript

Bio-Path Holdings, Inc (BPTH) CEO Peter Nielsen on Q3 2019 Results - Earnings Call Transcript

on Seeking Alpha

10-Q: BIO-PATH HOLDINGS INC

10-Q: BIO-PATH HOLDINGS INC

on Edgar Online - (EDG = 10Q, 10K)

Microcaps mostly among midday movers

Microcaps mostly among midday movers

on Seeking Alpha

H.C. Wainwright Keeps Their Buy Rating on Bio-Path Holdings (BPTH)

In a report released today, Yi Chen from H.C.[...]

on SmarterAnalyst

Bio-Path nabs new patent in U.S.

Bio-Path nabs new patent in U.S.

on Seeking Alpha

Bio-Path Holdings (BPTH) Investor Presentation - Slideshow

Bio-Path Holdings (BPTH) Investor Presentation - Slideshow

on Seeking Alpha

Bio-Path doses patient in amended mid-stage prexigebersen trial; shares up 5% premarket

on Seeking Alpha

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q2 2019 Results - Earnings Call Transcript

on Seeking Alpha

AVRO, NUS, SCPL and SGEN among midday movers

on Seeking Alpha

Microcaps mostly among midday movers

on Seeking Alpha

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2019 Results - Earnings Call Transcript

on Seeking Alpha

WIX and FTCH among premarket losers

on Seeking Alpha

10-Q: BIO-PATH HOLDINGS INC

on Edgar Online - (EDG = 10Q, 10K)

University Of Texas Investment Managment Co Buys Bio-Path Holdings Inc, Amarin Corp PLC, ...

on GuruFocus.com

3 Big Stock Charts for Tuesday: Hanesbrands, Omnicom Group and Schlumberger

on InvestorPlace.com

Antisense Oligonucleotides Market to Gain a Stronghold by 2027

Antisense Oligonucleotides Market to Gain a Stronghold by 2027

on Markitwired

Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

on GlobeNewswire

Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

on GlobeNewswire

Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

on GlobeNewswire

Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

on GlobeNewswire

BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Entry into a Material Definitive Agreement

BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Entry into a Material Definitive Agreement

on Market Exclusive

Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market

on GlobeNewswire

Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market

on GlobeNewswire

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002

on GlobeNewswire

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002

on GlobeNewswire

Bio-Path Holdings Reports Third Quarter 2019 Financial Results

Bio-Path Holdings Reports Third Quarter 2019 Financial Results

on GlobeNewswire

Bio-Path Holdings Reports Third Quarter 2019 Financial Results

Bio-Path Holdings Reports Third Quarter 2019 Financial Results

on GlobeNewswire

Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

on GlobeNewswire

Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

on GlobeNewswire

Thyroid Cancer Drugs Market Opportunities, Developments, Market Size and Future Forecasts To 2026

Thyroid Cancer Drugs Market Opportunities, Developments, Market Size and Future Forecasts To 2026

on marketresearch.biz

Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

on GlobeNewswire

Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

on GlobeNewswire

Sales Revenue of Antisense Oligonucleotides Market research to Soar in the Near Future Owing to Growing Consumer Adoption

Sales Revenue of Antisense Oligonucleotides Market research to Soar in the Near Future Owing to Growing Consumer Adoption

on Markitwired

Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent

Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent

on GlobeNewswire

Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent

Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent

on GlobeNewswire

Bio-Path Holdings Inc.

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX. (See Full Profile)

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1 Full Ratings